SCHEMBL3136623

SCHEMBL3136623

CNC(=O)CCc1ccccc1CC(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.45
MTNR1B P49286 1/20 0.45
GABRA1 P14867 1/20 0.43
GABRB2 P47870 1/20 0.43
MAPT P10636 2/20 0.42
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
EGFR P00533 1/20 0.40
SRC P12931 1/20 0.40
NR4A2 P43354 1/20 0.40
ALDH1A1 P00352 3/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC6A3 Q01959 1/20 0.38
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26741629 0.85 ALDH1A1 (0.48) GABRA1GABRB2MAPTALDH1A1HPGD
SCHEMBL3146180 0.83 EGFR (0.44) GABRA1GABRB2MAPTEGFRSRC
SCHEMBL3156228 0.83 MAPT (0.57) MAPTALDH1A1GAAHPGD
SCHEMBL3150970 0.81 LMNA (0.46) MAPTALDH1A1GAAHPGD
SCHEMBL8083913 0.81 ALDH1A1 (0.51) MTNR1AMTNR1BGABRA1GABRB2MAPT
SCHEMBL1394337 0.81 KEAP1 (0.48) GABRA1GABRB2ALDH1A1
SCHEMBL27566829 0.79 GABRA1 (0.46) GABRA1GABRB2MAPTALDH1A1HPGD
SCHEMBL3068210 0.77 HSPA5 (0.48) MTNR1AMTNR1BCCNCCDK8EGFR
SCHEMBL363391 0.77 NOTUM (0.56) MTNR1AMTNR1BCCNCCDK8EGFR
SCHEMBL6283252 0.76 MTNR1A (0.39) MTNR1AMTNR1BGABRA1GABRB2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP claimed
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 MTNR1A 1747/4885MTNR1B 1016/4885GABRA1 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.